Compare Dollar General Corp. (DG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Revvity Inc — how do they compare? Dollar General Corp. trades at $119.54 (market cap $26.49B), while Revvity Inc trades at $116.16 (market cap $12.91B). The key difference: Dollar General Corp. is far larger — about 2.1× Revvity Inc's market cap, and Dollar General Corp. pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| DG | RVTY | |
|---|---|---|
Market Cap | $26.49B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $156.26 | $117.75 |
52-Week Low | $95.94 | $82.26 |
Enterprise Value | $40.93B | $15.23B |
Dividend Yield | 1.97% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.39, down 3.32% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.00 surpassing the $1.89 expectation. Positive cash flow trends and a declining debt-to-asset ratio (20.03 in 2025) support financial health. A dividend of $0.59 is scheduled for payment on July 21, 2026.
The outlook is cautiously optimistic, with a consensus price target of $128.45 offering ~5% upside. Analyst sentiment is bullish (52% Buy ratings), but risks include competitive pressure from Walmart and Amazon, margin compression from rising costs, and market saturation. Revenue growth is projected to reach $43.1B in 2026, though net margin remains thin at 3.63%.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
